Article ; Online: Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series.
Journal of the neurological sciences
2020 Volume 420, Page(s) 117263
Abstract: ... reviews that includes GBS variants and the clinical prediction tool mEGOS for prognostication in COVID-19 ... Reports of COVID-19 with central (CNS) and peripheral nervous (PNS) system manifestations are emerging ... PubMed, Scopus, and Google Scholar) for studies on COVID-19 and GBS between December 1, 2019 to July 15 ...
| Abstract | Background: The COVID-19 pandemic caused by SARS-COV-2 began in Wuhan, China in December 2019. Reports of COVID-19 with central (CNS) and peripheral nervous (PNS) system manifestations are emerging. In this systematic review, we compared and summarized the demographics, clinical features, Brighton criteria, immunological and laboratory findings with a focus on modified Erasmus GBS Outcome Score (mEGOS) in SARS-CoV-2 patients with GBS and its variants. Methods: Based on PRISMA guidelines, we searched three databases (PubMed, Scopus, and Google Scholar) for studies on COVID-19 and GBS between December 1, 2019 to July 15, 2020. For descriptive analysis, we studied two groups with: 1) acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, and 2) Non-AIDP/Other variants. We compared mEGOS scores for patients in both groups along with other key clinical features. Results: Of the 50 GBS cases identified from 37 studies, 33 (66%) had acute inflammatory demyelinating polyradiculopolyneuropathy (AIDP) while 17 (34%) were of other (non-AIDP) variants. There mEGOS scores did not differ between AIDP patients and AMAN/AMSAN patients. Majority of the AIDP (66.7%) and AMAN/AMSAN (57.2%) patients belonged to Brighton level 1 indicating maximum diagnostic certainty. Conclusion: To our knowledge, this is among the first reviews that includes GBS variants and the clinical prediction tool mEGOS for prognostication in COVID-19 patients. Further research is needed to assess whether IVIG is preferable over plasmapheresis in this population of GBS patients. It would also be crucial to follow these patients over time to identify the long-term disability as well as treatment outcomes. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | COVID-19/complications ; COVID-19/physiopathology ; Guillain-Barre Syndrome/etiology ; Guillain-Barre Syndrome/physiopathology ; Humans ; Neural Conduction/physiology | |||||
| Language | English | |||||
| Publishing date | 2020-12-09 | |||||
| Publishing country | Netherlands | |||||
| Document type | Journal Article ; Systematic Review | |||||
| ZDB-ID | 80160-4 | |||||
| ISSN | 1878-5883 ; 0022-510X ; 0374-8642 | |||||
| ISSN (online) | 1878-5883 | |||||
| ISSN | 0022-510X ; 0374-8642 | |||||
| DOI | 10.1016/j.jns.2020.117263 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 308: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.